Interim data shows broad hematologic correction including improved hemoglobin levels and reduction in LDH CRESTWOOD, KY. and WALTHAM, MA., April 16, 2018 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of…
Initially founded with capital from leading healthcare investor Epidarex Capital, Enterprise raises Series B round co-led by Versant Ventures and Novartis Venture Fund, with Forbion, Epidarex Capital and IP Group completing the syndicate Funding will advance pipeline of novel treatments for respiratory diseases into clinical…
Cambridge, UK, 04 April 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it will collaborate with IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. The project will add…
March 26, 2018 – Mironid is delighted to announce the appointment of Prof Dorien Peters to our Scientific Advisory Board Prof. Dr. Dorien Peters is a molecular geneticist and cellular biologist at the Leiden University Medical Center in the Netherlands. Her research aims to obtain…
Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner. 21 March 2018 – EM Imaging, based in Edinburgh, is partnering with Bowel Cancer UK and Beating Bowel Cancer to raise funds for the charity and increase awareness of Scotland’s…
An excerpt for an article written by Morgan Eichensehr, originally published in the Baltimore Business Journal March 16, 2018 – Harpoon Medical Inc.’s $100 million sale to a Southern California medical device company was a deal two years in the making. Bill Niland, the former…
March 5, 2018 – Mironid is delighted to announce the appointment of Dr Steve Felstead as Chief Medical Officer (CMO) Dr Felstead retired from the position of Vice President, Head of Clinical Research, Pharmatherapeutics Division, Pfizer Inc in April 2014. He joined Pfizer in 1989,…
Data supports biologic activity of APL-2 in reducing the growth rate of geographic atrophy CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, today will…
Third sector funder Inspiring Scotland has appointed Sinclair Dunlop of Epidarex Capital as chair of its board of trustees. He succeeds Niall Lothian, who has led the board since Inspiring Scotland was founded in 2008. Today’s announcement coincides with the 10th anniversary of Inspiring Scotland….
Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million. Topas Therapeutics will act as exclusive partner for indication expansions and translation of research results into clinical development. Hamburg, 25th…